Aspira Women's Health Inc. (AWH) Stock Analysis

Aspira Women's Health Inc. (AWH) Healthcare & Pipeline Overview

Aspira Women's Health Inc. specializes in diagnostic tests for gynecologic diseases, including ovarian cancer risk assessment and genetic testing for gynecologic cancer risk. Their product suite, including OVA1 and ASPiRA GenetiX, serves physicians and laboratories, positioning them in the women's health diagnostics market.

What Is the Investment Thesis for AWH?

Aspira Women's Health operates in the women's health diagnostics market, with a focus on ovarian cancer risk assessment and genetic testing for gynecologic cancers. The company's gross margin of 64.2% indicates a strong pricing power. Key growth catalysts include the potential commercialization of pipeline products like OVAWatch, EndoCheck, and OVAInherit. The company's collaborative agreements with institutions like Baylor Genetics and Quest Diagnostics could drive innovation and market penetration. However, the company's negative profit margin of -138.7% and a market cap of $2.46M raise concerns about its financial sustainability. Investors should closely monitor the company's ability to achieve profitability and effectively commercialize its pipeline products.

Based on FMP financials and quantitative analysis

AWH Key Highlights

Gross Margin of 64.2% indicates strong pricing power in the diagnostic testing market.

• Profit Margin of -138.7% reflects significant losses and highlights the need for improved cost management.
• Market Cap of $2.46M indicates the company is a micro-cap stock with high volatility.
• Beta of 2.01 suggests the stock is more volatile than the market, potentially offering higher returns but also greater risk.
• Collaborative agreements with Baylor Genetics and Quest Diagnostics provide access to advanced technologies and broader market reach.

Who Are AWH's Competitors?

AWH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AWH's Key Strengths?

Proprietary diagnostic tests for ovarian cancer risk assessment.

• ASPiRA LABS provides specialized testing services.
• Collaborative agreements with leading research institutions.
• Established relationships with physicians and laboratories.

What Are AWH's Weaknesses?

Negative profit margin indicates financial instability.

• Limited market capitalization restricts access to capital.
• Reliance on a small number of diagnostic tests.
• Limited geographic reach.

What Could Drive AWH Stock Higher?

AWH catalyst: Potential commercialization of OVAWatch, providing continuous monitoring for women at high risk of ovarian cancer.

• Expansion of ASPiRA GenetiX to include additional genetic markers and target new patient populations.
• Leveraging strategic alliances with Baylor Genetics and Quest Diagnostics for technology development and market expansion.
• Development and commercialization of EndoCheck for endometriosis diagnosis.
• Development and commercialization of OVAInherit for hereditary ovarian cancer risk assessment.

What Are the Key Risks for AWH?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Competition from established diagnostic companies with greater resources.
• Regulatory changes and reimbursement policies impacting market access and profitability.
• Technological obsolescence rendering existing diagnostic tests outdated.
• Negative profit margin and limited market capitalization raising concerns about financial sustainability.
• Patent expiration and intellectual property infringement threatening market exclusivity.

What Are the Growth Opportunities for AWH?

• Commercialization of OVAWatch: OVAWatch, a pipeline product, represents a significant growth opportunity for Aspira. This product aims to provide continuous monitoring for women at high risk of developing ovarian cancer. The market for continuous monitoring devices in oncology is expanding, driven by the need for early detection and personalized treatment plans. Successful commercialization of OVAWatch could significantly increase Aspira's revenue and market share within the next 3-5 years.
• Expansion of ASPiRA GenetiX: ASPiRA GenetiX, a genetic test for gynecologic cancer risk, can be expanded to include additional genetic markers and target new patient populations. The market for genetic testing is growing rapidly, fueled by advancements in genomics and increasing awareness of personalized medicine. By enhancing the capabilities of ASPiRA GenetiX, Aspira can capture a larger share of the genetic testing market and drive revenue growth over the next 2-3 years.
• Strategic Alliances and Partnerships: Aspira's collaborative agreements with Baylor Genetics, Harvard Dana-Farber Cancer Institute, and Quest Diagnostics provide opportunities for technology development and market expansion. These partnerships can accelerate the development of new diagnostic tests and expand the company's reach to new customer segments. Leveraging these partnerships effectively can drive revenue growth and enhance Aspira's competitive position within the next 1-2 years.
• Geographic Expansion: Aspira Women's Health can expand its geographic reach beyond the United States to international markets. The global market for gynecologic cancer diagnostics is growing, driven by increasing incidence rates and rising healthcare expenditure. By entering new markets, Aspira can diversify its revenue streams and reduce its reliance on the U.S. market. This expansion could take place over the next 3-5 years, depending on regulatory approvals and market access strategies.
• Development of EndoCheck and OVAInherit: Aspira's pipeline products, EndoCheck and OVAInherit, represent additional growth opportunities. EndoCheck aims to diagnose endometriosis, while OVAInherit focuses on hereditary ovarian cancer risk assessment. Successful development and commercialization of these products can expand Aspira's product portfolio and address unmet needs in women's health. These products could be launched within the next 2-4 years, pending clinical trials and regulatory approvals.

What Are AWH's Competitive Advantages?

• Proprietary diagnostic tests for gynecologic diseases.
• Specialized laboratory services through ASPiRA LABS.
• Collaborative agreements with leading research institutions.
• Established relationships with physicians and laboratories.

What Does AWH Do?

Aspira Women's Health Inc., originally incorporated in 1993 and formerly known as Vermillion, Inc. until June 2020, is dedicated to the development and commercialization of diagnostic tests focused on gynecologic diseases in the United States. Headquartered in Austin, Texas, the company's core mission revolves around addressing critical needs in the management of gynecologic cancers and diseases through innovative biomarker-based technologies. Aspira's product portfolio includes OVA1, OVERA, and OVA1plus, which are designed to detect the risk of ovarian malignancy in women presenting with adnexal masses. The company also offers ASPiRA GenetiX, a genetic test aimed at assessing the risk of gynecologic cancer. These diagnostic solutions are primarily targeted towards physicians, physician office laboratories, and national and regional laboratories. In addition to its diagnostic tests, Aspira Women's Health operates Aspira Synergy, a testing platform and cloud service that provides decentralized access to protein biomarker and hereditary genetic testing. The company also owns and operates ASPiRA LABS, a laboratory specializing in the application of biomarker-based technologies. Aspira Women's Health has several collaborative agreements, including partnerships with Baylor Genetics, Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, Medical University Lodz, and Quest Diagnostics, Incorporated, to further research and development efforts.

What Products and Services Does AWH Offer?

• Develop and commercialize diagnostic tests for gynecologic diseases.
• Provide OVA1, OVERA, and OVA1plus to detect the risk of ovarian malignancy.
• Offer ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer.
• Operate Aspira Synergy, a testing platform for biomarker and genetic testing.
• Own and operate ASPiRA LABS, specializing in biomarker-based technologies.
• Develop pipeline products including OVAWatch, EndoCheck, and OVAInherit.

How Does AWH Make Money?

• Generate revenue through the sale of diagnostic tests to physicians and laboratories.
• Offer testing services through ASPiRA LABS.
• License technology and collaborate with partners for research and development.
• Provide access to testing platforms and cloud services through Aspira Synergy.

What Industry Does AWH Operate In?

Aspira Women's Health operates within the medical diagnostics and research industry, which is characterized by rapid technological advancements and increasing demand for personalized medicine. The market for gynecologic cancer diagnostics is driven by the need for early and accurate detection to improve patient outcomes. Aspira competes with other diagnostic companies, including those offering genetic testing and biomarker-based assays. The industry is also subject to regulatory oversight and reimbursement policies, which can impact market access and profitability.

Who Are AWH's Key Customers?

• Physicians specializing in women's health.
• Physician office laboratories.
• National and regional laboratories.
• Hospitals and medical centers.

Company Profile

Aspira Women's Health Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Nicolette Possemato. AWH has traded publicly since 2000.

Return on equity for Aspira Women's Health Inc. stands at 203.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.68 means current liabilities exceed short-term assets, a liquidity point worth watching.

AWH Valuation & Market Position

With a $2.46M market cap, Aspira Women's Health Inc. sits in the micro-cap segment of the market.

Quarterly Financial Performance: Aspira Women's Health Inc.

Revenue for Aspira Women's Health Inc. came in at $2.0M during Q2 2026, a 4.0% improvement versus the preceding quarter. The company recorded a net loss of $2.4M, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, AWH averaged $-0.06 in diluted EPS.

Aspira Women's Health Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Wall Street analysts project Aspira Women's Health Inc. revenue of about $32.7M for fiscal 2026, with EPS near $-0.26.

AWH Financials

AWH Latest News

No recent news available for AWH.

Common Questions About AWH (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources